journal
MENU ▼
Read by QxMD icon Read
search

New England Journal of Medicine

journal
https://read.qxmd.com/read/30865819/hypertension-hot-potato-anatomy-of-the-angiotensin-receptor-blocker-recalls
#1
J Brian Byrd, Glenn M Chertow, Vivek Bhalla
No abstract text is available yet for this article.
March 13, 2019: New England Journal of Medicine
https://read.qxmd.com/read/30865791/a-trial-of-a-shorter-regimen-for-rifampin-resistant-tuberculosis
#2
Andrew J Nunn, Patrick P J Phillips, Sarah K Meredith, Chen-Yuan Chiang, Francesca Conradie, Doljinsuren Dalai, Armand van Deun, Phan-Thuong Dat, Ngoc Lan, Iqbal Master, Tesfamarium Mebrahtu, Daniel Meressa, Ronelle Moodliar, Nosipho Ngubane, Karen Sanders, Stephen Bertel Squire, Gabriela Torrea, Bazarragchaa Tsogt, I D Rusen
BACKGROUND: Cohort studies in Bangladesh showed promising cure rates among patients with multidrug-resistant tuberculosis who received existing drugs in regimens shorter than that recommended by the World Health Organization (WHO) in 2011. METHODS: We conducted a phase 3 noninferiority trial in participants with rifampin-resistant tuberculosis that was susceptible to fluoroquinolones and aminoglycosides. Participants were randomly assigned, in a 2:1 ratio, to receive a short regimen (9 to 11 months) that included high-dose moxifloxacin or a long regimen (20 months) that followed the 2011 WHO guidelines...
March 13, 2019: New England Journal of Medicine
https://read.qxmd.com/read/30865790/a-short-regimen-for-rifampin-resistant-tuberculosis
#3
EDITORIAL
Gavin J Churchyard
No abstract text is available yet for this article.
March 13, 2019: New England Journal of Medicine
https://read.qxmd.com/read/30840790/an-epidemic-of-suspicion-ebola-and-violence-in-the-drc
#4
Vinh-Kim Nguyen
No abstract text is available yet for this article.
March 6, 2019: New England Journal of Medicine
https://read.qxmd.com/read/30817865/the-devil-is-in-the-details
#5
(no author information available yet)
New England Journal of Medicine, Volume 380, Issue 11, Page 1090-1090, March 2019.
February 28, 2019: New England Journal of Medicine
https://read.qxmd.com/read/30811904/opioid-use-disorder-and-incarceration-hope-for-ensuring-the-continuity-of-treatment
#6
Ingrid A Binswanger
No abstract text is available yet for this article.
February 27, 2019: New England Journal of Medicine
https://read.qxmd.com/read/30786182/the-fda-s-proposed-ban-on-menthol-cigarettes
#7
Keith Wailoo
No abstract text is available yet for this article.
February 20, 2019: New England Journal of Medicine
https://read.qxmd.com/read/30786181/retraction-steering-car-t-cells-into-solid-tumors-n-engl-j-med-2019-380-289-91
#8
LETTER
Marion H Brown, Michael L Dustin
No abstract text is available yet for this article.
February 20, 2019: New England Journal of Medicine
https://read.qxmd.com/read/30779530/adjunctive-intermittent-pneumatic-compression-for-venous-thromboprophylaxis
#9
Yaseen M Arabi, Fahad Al-Hameed, Karen E A Burns, Sangeeta Mehta, Sami J Alsolamy, Mohammed S Alshahrani, Yasser Mandourah, Ghaleb A Almekhlafi, Mohammed Almaani, Ali Al Bshabshe, Simon Finfer, Zia Arshad, Imran Khalid, Yatin Mehta, Atul Gaur, Hassan Hawa, Hergen Buscher, Hani Lababidi, Abdulsalam Al Aithan, Sheryl A I Abdukahil, Jesna Jose, Lara Y Afesh, Abdulaziz Al-Dawood
BACKGROUND: Whether adjunctive intermittent pneumatic compression in critically ill patients receiving pharmacologic thromboprophylaxis would result in a lower incidence of deep-vein thrombosis than pharmacologic thromboprophylaxis alone is uncertain. METHODS: We randomly assigned patients who were considered adults according to the local standards at the participating sites (≥14, ≥16, or ≥18 years of age) within 48 hours after admission to an intensive care unit (ICU) to receive either intermittent pneumatic compression for at least 18 hours each day in addition to pharmacologic thromboprophylaxis with unfractionated or low-molecular-weight heparin (pneumatic compression group) or pharmacologic thromboprophylaxis alone (control group)...
February 18, 2019: New England Journal of Medicine
https://read.qxmd.com/read/30779528/bag-mask-ventilation-during-tracheal-intubation-of-critically-ill-adults
#10
Jonathan D Casey, David R Janz, Derek W Russell, Derek J Vonderhaar, Aaron M Joffe, Kevin M Dischert, Ryan M Brown, Aline N Zouk, Swati Gulati, Brent E Heideman, Michael G Lester, Alexandra H Toporek, Itay Bentov, Wesley H Self, Todd W Rice, Matthew W Semler
BACKGROUND: Hypoxemia is the most common complication during tracheal intubation of critically ill adults and may increase the risk of cardiac arrest and death. Whether positive-pressure ventilation with a bag-mask device (bag-mask ventilation) during tracheal intubation of critically ill adults prevents hypoxemia without increasing the risk of aspiration remains controversial. METHODS: In a multicenter, randomized trial conducted in seven intensive care units in the United States, we randomly assigned adults undergoing tracheal intubation to receive either ventilation with a bag-mask device or no ventilation between induction and laryngoscopy...
February 18, 2019: New England Journal of Medicine
https://read.qxmd.com/read/30779527/preventing-dogma-from-driving-practice
#11
EDITORIAL
Patricia A Kritek, Andrew M Luks
No abstract text is available yet for this article.
February 18, 2019: New England Journal of Medicine
https://read.qxmd.com/read/30779531/avelumab-plus-axitinib-versus-sunitinib-for-advanced-renal-cell-carcinoma
#12
Robert J Motzer, Konstantin Penkov, John Haanen, Brian Rini, Laurence Albiges, Matthew T Campbell, Balaji Venugopal, Christian Kollmannsberger, Sylvie Negrier, Motohide Uemura, Jae L Lee, Aleksandr Vasiliev, Wilson H Miller, Howard Gurney, Manuela Schmidinger, James Larkin, Michael B Atkins, Jens Bedke, Boris Alekseev, Jing Wang, Mariangela Mariani, Paul B Robbins, Aleksander Chudnovsky, Camilla Fowst, Subramanian Hariharan, Bo Huang, Alessandra di Pietro, Toni K Choueiri
BACKGROUND: In a single-group, phase 1b trial, avelumab plus axitinib resulted in objective responses in patients with advanced renal-cell carcinoma. This phase 3 trial involving previously untreated patients with advanced renal-cell carcinoma compared avelumab plus axitinib with the standard-of-care sunitinib. METHODS: We randomly assigned patients in a 1:1 ratio to receive avelumab (10 mg per kilogram of body weight) intravenously every 2 weeks plus axitinib (5 mg) orally twice daily or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle)...
February 16, 2019: New England Journal of Medicine
https://read.qxmd.com/read/30779529/pembrolizumab-plus-axitinib-versus-sunitinib-for-advanced-renal-cell-carcinoma
#13
Brian I Rini, Elizabeth R Plimack, Viktor Stus, Rustem Gafanov, Robert Hawkins, Dmitry Nosov, Frédéric Pouliot, Boris Alekseev, Denis Soulières, Bohuslav Melichar, Ihor Vynnychenko, Anna Kryzhanivska, Igor Bondarenko, Sergio J Azevedo, Delphine Borchiellini, Cezary Szczylik, Maurice Markus, Raymond S McDermott, Jens Bedke, Sophie Tartas, Yen-Hwa Chang, Satoshi Tamada, Qiong Shou, Rodolfo F Perini, Mei Chen, Michael B Atkins, Thomas Powles
BACKGROUND: The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes than sunitinib in such patients was unclear. METHODS: In an open-label, phase 3 trial, we randomly assigned 861 patients with previously untreated advanced clear-cell renal-cell carcinoma to receive pembrolizumab (200 mg) intravenously once every 3 weeks plus axitinib (5 mg) orally twice daily (432 patients) or sunitinib (50 mg) orally once daily for the first 4 weeks of each 6-week cycle (429 patients)...
February 16, 2019: New England Journal of Medicine
https://read.qxmd.com/read/30779526/combination-therapy-as-first-line-treatment-in-metastatic-renal-cell-carcinoma
#14
EDITORIAL
Bernard Escudier
No abstract text is available yet for this article.
February 16, 2019: New England Journal of Medicine
https://read.qxmd.com/read/30767714/angiotensin-neprilysin-inhibition-in-acute-decompensated-heart-failure
#15
(no author information available yet)
No abstract text is available yet for this article.
February 15, 2019: New England Journal of Medicine
https://read.qxmd.com/read/30763142/darolutamide-in-nonmetastatic-castration-resistant-prostate-cancer
#16
Karim Fizazi, Neal Shore, Teuvo L Tammela, Albertas Ulys, Egils Vjaters, Sergey Polyakov, Mindaugas Jievaltas, Murilo Luz, Boris Alekseev, Iris Kuss, Christian Kappeler, Amir Snapir, Toni Sarapohja, Matthew R Smith
BACKGROUND: Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer. METHODS: We conducted a randomized, double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic, castration-resistant prostate cancer and a prostate-specific antigen doubling time of 10 months or less...
February 14, 2019: New England Journal of Medicine
https://read.qxmd.com/read/30763143/genetic-susceptibility-to-alopecia
#17
Jouni Uitto
New England Journal of Medicine, Volume 380, Issue 9, Page 873-876, February 2019.
February 13, 2019: New England Journal of Medicine
https://read.qxmd.com/read/30763140/variant-padi3-in-central-centrifugal-cicatricial-alopecia
#18
Liron Malki, Ofer Sarig, Maria-Teresa Romano, Marie-Claire Méchin, Alon Peled, Mor Pavlovsky, Emily Warshauer, Liat Samuelov, Laura Uwakwe, Valeria Briskin, Janan Mohamad, Andrea Gat, Ofer Isakov, Tom Rabinowitz, Noam Shomron, Noam Adir, Michel Simon, Amy McMichael, Ncoza C Dlova, Regina C Betz, Eli Sprecher
BACKGROUND: Central centrifugal cicatricial alopecia (CCCA) is the most common form of scarring alopecia among women of African ancestry. The disease is occasionally observed to affect women in families in a manner that suggests an autosomal dominant trait and usually manifests clinically after intense hair grooming. We sought to determine whether there exists a genetic basis of CCCA and, if so, what it is. METHODS: We used exome sequencing in a group of women with alopecia (discovery set), compared the results with those in a public repository, and applied other filtering criteria to identify candidate genes...
February 13, 2019: New England Journal of Medicine
https://read.qxmd.com/read/30730782/full-study-report-of-andexanet-alfa-for-bleeding-associated-with-factor-xa-inhibitors
#19
Stuart J Connolly, Mark Crowther, John W Eikelboom, C Michael Gibson, John T Curnutte, John H Lawrence, Patrick Yue, Michele D Bronson, Genmin Lu, Pamela B Conley, Peter Verhamme, Jeannot Schmidt, Saskia Middeldorp, Alexander T Cohen, Jan Beyer-Westendorf, Pierre Albaladejo, Jose Lopez-Sendon, Andrew M Demchuk, Daniel J Pallin, Mauricio Concha, Shelly Goodman, Janet Leeds, Sonia Souza, Deborah M Siegal, Elena Zotova, Brandi Meeks, Sadia Ahmad, Juliet Nakamya, Truman J Milling
BACKGROUND: Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors. METHODS: We evaluated 352 patients who had acute major bleeding within 18 hours after administration of a factor Xa inhibitor. The patients received a bolus of andexanet, followed by a 2-hour infusion. The coprimary outcomes were the percent change in anti-factor Xa activity after andexanet treatment and the percentage of patients with excellent or good hemostatic efficacy at 12 hours after the end of the infusion, with hemostatic efficacy adjudicated on the basis of prespecified criteria...
February 7, 2019: New England Journal of Medicine
https://read.qxmd.com/read/30699301/effect-of-adding-azithromycin-to-seasonal-malaria-chemoprevention
#20
Daniel Chandramohan, Alassane Dicko, Issaka Zongo, Issaka Sagara, Matthew Cairns, Irene Kuepfer, Modibo Diarra, Amadou Barry, Amadou Tapily, Frederic Nikiema, Serge Yerbanga, Samba Coumare, Ismaila Thera, Abdourhamane Traore, Paul Milligan, Halidou Tinto, Ogobara Doumbo, Jean-Bosco Ouedraogo, Brian Greenwood
BACKGROUND: Mass administration of azithromycin for trachoma control led to a sustained reduction in all-cause mortality among Ethiopian children. Whether the addition of azithromycin to the monthly sulfadoxine-pyrimethamine plus amodiaquine used for seasonal malaria chemoprevention could reduce mortality and morbidity among African children was unclear. METHODS: We randomly assigned children 3 to 59 months of age, according to household, to receive either azithromycin or placebo, together with sulfadoxine-pyrimethamine plus amodiaquine, during the annual malaria-transmission season in Burkina Faso and Mali...
January 30, 2019: New England Journal of Medicine
journal
journal
20199
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"